Fisher Scientific International Inc

Fisher Scientific International — Merger or Acquisition (May 2004)

23 slides from Fisher Scientific International's merger presentation, May 21, 2004

  1. Slide 1: The World Leader in Serving Science

    The World Leader in Serving Science May 2004

  2. Slide 2: Safe Harbor and Regulation G Statement

    The statements in this presentation which are not historical facts or information are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in our 2003

  3. Slide 3: The Preferred Partner

    The Preferred Partner Providing a broad product and service offering to approximately 350,000 customers in 145 countries Research and Development Drug Discovery Drug Development Healthcare Delivery Fisher Scientific

  4. Slide 4: Diverse Customer Base

    Scientific Research 75% Clinical Lab 25% No Customer > 2.5% of Sales Diverse Customer Base Pharma 0.23 Hospitals 0.17 Reference Labs / Other 0.08 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11

  5. Slide 5: Market Dynamics are Favorable

    Market Dynamics are Favorable Pressure on drug development costs Aging population R&D spending steadily increasing Growth in homeland security spending Demand for low cost solutions More diagnostic testing Research market growing Demand for safety related products

  6. Slide 6: Scientific Research Market Leadership Position

    Scientific Research Market 11 Leadership position Global Market Size: $20 Billion Growth Rate: 5 - 8% U.S. R&D Spending CAGR: 9% 1960 1965 1970 1975 1980 1985 1990 1995 2003 (Excl. Defense and Electronics) ($ in billions) Sources: Laboratory Products Association, SDI Inc., SAI, and management estima

  7. Slide 7: Scientific Products and Services

    Scientific Products and Services 13 Proprietary protein, DNA and cell culture products Fine and high purity chemicals General lab supplies and consumables Pharmaceutical services

  8. Slide 8: Clinical Lab Market Leading Position

    Clinical Lab Market 15 Leading position U.S. Market Size: $9.5 Billion Growth Rate: 4 - 5% Number of IVD Tests (Test Per Person) IVD Tests (in Bils) 1989 1993 1998 2003 2008 East 13.3 14.5 16.5 19.1 22 3.3 3.8 4.5 5.4 6.5 Sources: The Freedonia Group and management estimates.

  9. Slide 9: Company Capabilities

    Premier brands Industry-leading sales force Globally integrated supply chain Company Capabilities

  10. Slide 10: Industry-Leading Sales Force

    1,500 sales reps 1,200 customer service reps Industry-Leading Sales Force Company Capabilities Supply chain solutions 800* life science, chemical and technical specialists End-user sales and support * Includes effect of Apogent transaction.

  11. Slide 11: Globally Integrated Supply Chain

    Continually invest in leading edge technology Collaborate with our suppliers to drive supply chain efficiencies Company Capabilities Globally Integrated Supply Chain Provide customers with customized supply chain solutions

  12. Slide 12: Reduced Investment in Working Capital

    1998 1999 2000 2001 2002 2003 East 0.131 0.112 0.093 0.091 0.086 0.077 * Excludes impact of Perbio acquisition. Note: Working capital is defined as the average balance of the last four quarters of receivables plus inventories less accounts payable. As a Percentage of Sales * Company Capabilities Red

  13. Slide 13: Fisher Scientific: Powerful Channel Position

    Fisherbrand Fisher Chemicals Research and Development Drug Discovery Drug Development Fisher Scientific: Powerful Channel Position Healthcare Delivery Globally integrated logistics, industry-leading sales force

  14. Slide 14: Growth Strategy

    Growth Strategy 31 Increase proprietary product and service offering Capitalize on high growth life science market Increase earnings and cash flow growth

  15. Slide 15: Perbio Science

    Perbio Science Leading global manufacturer & supplier to life science and biopharmaceutical industries Kits and consumables for protein analysis Key components for the production of biotech drugs 100% consumable products End markets growing at 10 -15% annually Significant life science sales force

  16. Slide 16: Oxoid Group

    Oxoid Group Leading global manufacturer of microbiological products End markets growing 5 - 10% annually Significant specialty sales force Strong international presence

  17. Slide 17: Apogent Transaction Benefits

    Apogent Transaction Benefits Enhances portfolio of proprietary products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation Apogent - A perfect fit

  18. Slide 18: Financial Highlights

    Financial Highlights.

  19. Slide 19: Sales Growth

    Sales Growth ($ in Billions) 2000 2001 2002 2003 2004F* 2005F* *Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the impact of foreign exchange. CAGR: 16%

  20. Slide 20: Earnings Per Share Growth and Operating Margins

    Earnings Per Share Growth 2000 2001 2002 2003 2004F* 2005F* Excludes goodwill amortization, restructuring and nonrecurring expenses. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the effect of conversion of contingent convertible notes

  21. Slide 21: Strong Free Cash Flow

    Strong Free Cash Flow 2000 2001 2002 2003 2004F 2005F ($ in millions) Free cash flow is cash from operations less capital expenditures. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Memo: Debt-to-EBITDA 4.5x 3.5x 3.0x 3.6x 3.1x N/A * *

  22. Slide 22: Questions and Answers

    Questions and Answers 23 (Pee

  23. Slide 23: Supplementary Financial Information

    (in millions, except per share amounts) Supplementary Financial Information 53

Fisher Scientific International — Merger or Acquisition (May 2004) on 6ix